Regionalny Szpital Specjalistyczny Im. Dr. Wladyslawa Bieganskiego
- Address
- Ul. Dr. Ludwika Rydygiera 15/17, 86-300 Grudziądz, Poland
Cardiovascular Diseases
The cardiovascular diseases program at Regionalny Szpital Specjalistyczny focuses on improving outcomes for patients with acute heart conditions and post‑surgical complications.
- Acute Coronary Syndrome (ACS) management
- Outcomes after coronary artery bypass grafting (CABG)
- Prevention of acute kidney injury following cardiac surgery
- Iron‑deficiency treatment after recent myocardial infarction
- Optimization of antiplatelet strategies in stable coronary disease
The department leverages multidisciplinary expertise to test new therapies and refine standard care pathways for heart patients.
Neoplasms
Research on neoplasms at the site addresses a broad spectrum of solid tumors, aiming to evaluate innovative treatment combinations and improve survival.
- Advanced/metastatic breast cancer
- Metastatic castration‑resistant prostate cancer
- Metastatic colorectal cancer with c‑Met expression
- Metastatic non‑small cell lung cancer (NSCLC)
- Muscle‑invasive bladder cancer
Collaborative oncology trials evaluate novel agents, immunotherapies, and hormone‑targeted regimens to expand therapeutic options.
Nutritional and Metabolic Diseases
The department’s work in nutritional and metabolic diseases seeks to mitigate cachexia and anemia that often accompany chronic cardiac and oncologic conditions.
- Cancer‑associated cachexia management
- Iron‑deficiency anemia following myocardial infarction
- Metabolic support for heart‑failure patients
- Nutritional interventions to improve quality of life in oncology
By integrating metabolic assessments, the trials aim to enhance patient resilience and functional status.
Pathological Conditions, Signs and Symptoms
Studies targeting pathological conditions and related symptoms explore how procedural and medical interventions influence organ function and patient well‑being.
- Cardiac surgery‑associated acute kidney injury
- Heart‑failure events and hospitalization risk
- Graft failure after coronary artery bypass grafting
- Quality‑of‑life outcomes measured by standardized questionnaires
- Biomarker monitoring such as NT‑proBNP
The investigations combine clinical monitoring with patient‑reported outcomes to guide safer treatment protocols.
General Clinical Research
Across the institution, the clinical trials portfolio encompasses safety, efficacy, and comparative studies that address unmet medical needs in several therapeutic domains.
- Safety of antiplatelet de‑escalation strategies
- Evaluation of novel immunotherapy combinations
- Combination hormone therapies for advanced prostate cancer
- Dose‑optimization studies for targeted agents
- Comparative effectiveness research in oncology and cardiology
With 18 active trials and a team of seven investigators, the site contributes to advancing medical knowledge on both national and international levels.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 53 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 50 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Agencja Badań Medycznych2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Regionalny Szpital Specjalistyczny Im. Dr. Wladyslawa Bieganskiego
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Visugromab in Patients with Cancer-associated Cachexia | CatalYm GmbH | Phase IV | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 53 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Letrozole | 4 | Unknown | 2019-05-22 | 2025-05-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.